For instance, expression of CCL3, CCL5 and CXCL2 in melanoma-treated DRG cells increased up to 3.5-, 4- and 3-fold, respectively, compared to control DRG cells (p<0.05, n = 3, Fig 5B). This evidence concerns the gene CXCL2 and melanoma.